SAGE Therapeutics (SAGE) Tops Q2 EPS by 15c

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($0.79), $0.15 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $31.66 million versus the consensus estimate of $16.75 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• BofA lists top 5 themes driving next $1tn in incremental semi sales
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance